Preliminary randomized studies have failed to show a survival benefit of high-dose chemotherapy with alkylators in advanced breast cancer. Idarubicin is an active agent in breast cancer and is suitable for dose escalation. We designed a dose finding study with escalating high-dose idarubicin (HD-Ida) followed by fixed high-dose thiotepa+melphalan (HD-TM) with peripheral blood progenitor cells (PBPC) in MBC patients with stable disease or in partial response after six courses of induction chemotherapy with gemcitabine 1000 mg/m 2 days 1 and 4, epirubicin 90 mg/m 2 day 1, taxol 175 mg/m 2 day 1 (GET). Aims of the study were to identify the maximum tolerated dose (MTD) of idarubicin, to evaluate the cardiac safety and activity of HD-Ida and HD-TM after GET and to study the pharmacokinetic profile of idarubicin and idarubicinol. A total of 14 patients were treated. . Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively. No episodes of cardiac toxicity were observed. We conclude that HD-Ida followed by HD-TM is feasible and devoid of cardiac toxicity. Moreover, the activity of HD-Ida after a epirubicin-containing regimen suggests incomplete crossresistance between the two drugs. High-dose chemotherapy (HDC) with autologous hemopoietic support has been used as intensification/consolidation treatment in advanced breast cancer responsive to standard chemotherapy. However, despite encouraging preclinical data and phase II results, preliminary data from phase III randomized trials have failed to show any survival benefit.
Preliminary randomized studies have failed to show a survival benefit of high-dose chemotherapy with alkylators in advanced breast cancer. Idarubicin is an active agent in breast cancer and is suitable for dose escalation. We designed a dose finding study with escalating high-dose idarubicin (HD-Ida) followed by fixed high-dose thiotepa+melphalan (HD-TM) with peripheral blood progenitor cells (PBPC) in MBC patients with stable disease or in partial response after six courses of induction chemotherapy with gemcitabine 1000 mg/m 2 days 1 and 4, epirubicin 90 mg/m 2 day 1, taxol 175 mg/m 2 day 1 (GET). Aims of the study were to identify the maximum tolerated dose (MTD) of idarubicin, to evaluate the cardiac safety and activity of HD-Ida and HD-TM after GET and to study the pharmacokinetic profile of idarubicin and idarubicinol. A total of 14 patients were treated. Idarubicin was administered as a 48 h continuous i.v. infusion at the following dose levels: 40 mg/m 2 (three patients . Conversion rates after HD-Ida and HD-TM were 28.6 and 38.5%, respectively. No episodes of cardiac toxicity were observed. We conclude that HD-Ida followed by HD-TM is feasible and devoid of cardiac toxicity. Moreover, the activity of HD-Ida after a epirubicin-containing regimen suggests incomplete crossresistance between the two drugs. High-dose chemotherapy (HDC) with autologous hemopoietic support has been used as intensification/consolidation treatment in advanced breast cancer responsive to standard chemotherapy. However, despite encouraging preclinical data and phase II results, preliminary data from phase III randomized trials have failed to show any survival benefit. [1] [2] [3] [4] Most of the randomized trials have used four to six courses of induction chemotherapy followed by late intensification with a single course of HDC. High-dose regimens usually have included alkylating agents because of their steep dose-response curve, non-cell cycle specificity and broad clinical activity. 5 Attempts to improve these disappointing results include the development of more active induction regimens, the upfront use of HDC and sequential administration of high-dose drugs or regimens.
Our group has shown that the combination of gemcitabine+epirubicin+paclitaxel (GET) is very active with an overall response rate of 92% and a complete response rate of 31%; 6 the administration of high-dose thiotepa followed by high-dose melphalan as consolidation of GET induces an improvement in quality of response in 44% of patients. 7 On the basis of the promising activity and acceptable toxicity observed in this study, we were interested in evaluating the possibility of achieving further cell killing by administering another high-dose drug before high-dose alkylators.
Idarubicin, an anthracycline compound used for the treatment of acute myeloid leukemia, seemed a good candidate because of its reduced cardiotoxicity, 8 incomplete cross-resistance with other anthracyclines, 9 activity in breast cancer, 10, 11 and myelotoxicity as the most significant dose-limiting toxicity. 12 We therefore designed a dose finding study with escalating high-dose idarubicin (HD-Ida) followed by fixed high-dose thiotepa and melphalan (HD-TM) with autologous stem cell support in metastatic breast cancer patients with stable disease or in partial response after six courses of induction GET. End points of the study were: (1) to determine the maximum tolerated dose (MTD) of idarubicin with peripheral blood progenitor cells, (2) to determine the cardiac safety of HD-Ida followed by double high-dose alkylators, (3) to evaluate the activity of HD-Ida after GET, (4) to study the pharmacokinetic profile of idarubicin on plasma and cerebrospinal fluid (CSF).
Material and methods

Eligibility
Women o60 years old, performance status 0-1 (ECOG scale) with histologically confirmed metastatic breast cancer with stable disease or in partial remission (WHO criteria) following induction chemotherapy with GET were eligible for HDC treatment with peripheral blood progenitor cell (PBPC) support. Other eligibility criteria included left ventricular ejection fraction (L-VEF) 450%, as determined by bidimensional echocardiography, no history of cardiac abnormality, negative HBsAg, HCV and HIV. Prior hormone therapy and/or prior adjuvant chemotherapy were permitted. Patients with bone disease only were excluded. The presence of morphologically or immunohistochemically positive bone marrow was not an exclusion criterion. Patients were required to sign an informed consent and the Ethics Committee of St Chiara University Hospital approved the study.
Treatment plan
The GET regimen (gemcitabine 1000 mg/m 2 days 1 and 4, epirubicin 90 mg/m 2 day 1, paclitaxel 175 mg/m 2 over 3 h) was administered every 3 weeks for six courses. Before the third course of chemotherapy, a double lumen Arrow catheter was placed in the subclavian vein; starting from day 5 after the third course recombinant human granulocyte colony-stimulating factor (rhG-CSF) 5 mg/kg/day s.c. was given until an absolute CD34+ cell count X50/ml. At that point leukapheresis was performed on an outpatient basis using a Fenwall CS 3000 cell separator (Baxter, Chicago, IL, USA) or COBE Spectra; Whole blood (8-10 l) were processed per procedure using continuous flow centrifugation at a flow rate of 50 ml/min. The procedure was considered successful when a minimum of 5 Â 10 6 CD34+ cells/kg had been collected.
Within 6 weeks after the sixth course of GET, eligible patients were treated with HD-Id. The starting dose was 40 mg/m 2 , escalated by 10 mg/m 2 until dose-limiting toxicity. Idarubicin was infused over 48 h, patients were hydrated with 3000 ml/m 2 /day of isotonic saline solution and received prophylactic antiemetic therapy with dexamethasone 20 mg plus ondasentron 48 mg daily. Autologous PBPC were reinfused 216 h (9 days) after the end of the infusion in the first four patients and then, on the basis of the idarubicin and idarubicinol plasma levels, after 144 h (6 days) in the other 10 patients.
At the time of reinfusion, frozen PBPC were thawed rapidly in a 371C warm bath and reinfused through a central venous catheter; at least 3 Â 10 6 CD34+ cells/kg were reinfused. Following PBPC infusion, rhG-CSF 5 mg/ kg/day s.c. was administered until WBC 41000/ml for three consecutive days. Patients were housed in single rooms and received prophylactic oral ciprofloxacin, fluconazole and standard mouth care. Patients with a positive herpes titer were treated with acyclovir 500 mg i.v. every 12 h. In cases of febrile neutropenia ciprofloxacin was discontinued and i.v. ceftazidime and amikacin were administered. In cases of severe stomatitis, patients received total parenteral nutrition. All patients were tranfused with irradiated (25 Gy) leukocyte-free packed RBCs and single-donor platelets to maintain hemoglobin values above 9 g/dl and platelet counts greater than 15 000/ml. Patients were discharged when they had achieved an absolute neutrophil count greater than 500/ml, were able to tolerate an oral intake and required no more than one platelet unit daily.
After Hd-Id, the extent of their disease was fully reassessed and patients who were not in complete remission received a second course of HDC with thiotepa 600 mg/m 2 (day À3) and melphalan 160 mg/m 2 (day À1); thiotepa was administered divided in three equal doses as a 1 h infusion 1 h apart each; melphalan was administered 48 h after thiotepa divided in three equal doses as an i.v. bolus 2 h apart each. Autologous PBPC were reinfused 24 h after the end of chemotherapy and the same supportive procedures described above were adopted.
Safety and activity assessment
A complete restaging of disease extent was performed immediately before and after each course of HDC. Definition of response and toxicities were based on WHO criteria. 13 Dose-limiting toxicity of idarubicin was defined by one of the following toxicities: G3 stomatitis lasting more than 1 week, G4 stomatitis, G2 cardiotoxicity (decrease of L-VEF 415%). The MTD of idarubicin was considered the dose level immediately below that producing 1 DLT out of three patients. Cardiac monitoring consisted of clinical evaluation, ECG and B-mode echocardiography. L-VEF was determined before induction chemotherapy (baseline), at the end of induction treatment, after HD-Id, after high-dose alkylators, and every 3 months during follow-up. An ECG Holter registration was performed starting 4 h before until 24 h after the end of the idarubicin infusion. Parameters of cardiac toxicity were: clinical signs of heart failure, disorders of impulse formation or conduction and signs of ischemia, assessment of systolic function by L-VEF and diastolic function by equal/ abnormal (E/A) wave ratio. Time to progression and overall survival were calculated from first transplant according to Kaplan and Meier.
Pharmacokinetic analysis
Blood for pharmacokinetic studies was drawn immediately before the start of idarubicin, at 15 min, 1, 12, 24, 36 and 48 h during the infusion and at 10, 30 min, 1, 2, 4, 8, 12, 18, 24 h, then once daily for 8 days (216 h) after termination of the idarubicin infusion. Blood samples were collected in heparinized test tubes and plasma separated by centrifuga-tion for 15 min at 3600 rpm. A CSF sample was collected at the end of the idarubicin infusion in anticoagulant-free tubes. Samples were stored at -201C until analysis.
Idarubicin and idarubicinol levels were measured by a validated reversed-phase high-performance liquid chromatography method with liquid-liquid extraction and fluorescence detection.
14 Limits of quantitation of idarubicinidarubicinol were 0.5 ng/ml. Human blank plasma was used as a calibrant matrix and the method was linear (r 2 40.995, linear regression analysis, weighting 1/X 2 ) over the analytical range from 0.5 ng/ml to 5 mg/ml for idarubicin and idarubicinol. Accuracy (overall percent bias) of the assay was within the range of À1.8 to 6.2% for idarubicin and idarubicinol. Both intra-assay and interassay precision (coefficient of variation) were o7.5% for idarubicin and idarubicinol. The HPLC instrument was an LC Module I Plus equipped with a 715 autoinjector, a 486 variable wavelength UV detector and a 474 scanning fluorescence spectrophotometer (Waters, Milford, MA, USA). Peak plasma concentration (C max , ng/ml) and time to reach C max (T max , h) of parent drug and metabolite were determined graphically on the plasma concentration-time data and expressed as mean values7s.d. Half-lives (t 1/2 , h) were calculated as 0.
, where
) is the negative slope of the log-linear a, b, and g phases of the plasma concentration-time profiles. Finally, the area under the plasma concentration-time curve (zero moment curve, AUCt 0-264 , hng/ml) was calculated using the experimental values (trapezoidal rule).
Results
Patient characteristics
A total of 14 patients entered into the study. Median age was 55 (range 37-60); median performance status was 0 (ECOG); 50% of the patients had received adjuvant chemotherapy and visceral metastasis were present in 86% of patients; three patient had bone marrow involvement with a positive bone marrow biopsy. Nine patients (64%) were in partial response and five (36%) had stable disease after six courses of GET. Hormone receptor status was known in 11 patients and was negative in six (43%). Eight patients (57.1%) had received previous adjuvant chemotherapy not containing anthracycline. Before HD-Id, all patients had been treated for metastatic disease: cumulative doses of epirubicin and paclitaxel were 540 and 1050 mg/m 2 , respectively (Table 1) . In the first four patients PBPCs were reinfused 8 days after the end of the idarubicin infusion and in the other 10 patients PBPC reinfusion was performed 5 days after the end of the idarubicin infusion. Median times (range) to ANC 4500/ml and PLT 420 000/ml were 10 days (6-13) and 9 days (4-12), respectively. Median (range) duration of neutropenia with ANC o100/ml was 9 days (5-13) ( Table 2 ). There were no significant differences in terms of CD34+ cell dose, time to ANC and PLT recovery at the different idarubicin dose levels; moreover, there were no significant differences in terms of hemopoietic recovery and non-hematological toxicities in the two groups of patients transplanted 5 or 8 days after the end of the idarubicin infusion. We observed no CNS or pulmonary toxicity. Febrile neutropenia occurred in nine patients (66%) without documented infections.
Toxicity and hemopoietic recovery after thiotepa+melphalan
After a median of 37 days (range 26-45) following the first transplant, 12 patients received the second course of HDC with thiotepa plus melphalan.
The median number (range) of CD34+ cell/kg reinfused after thiotepa plus melphalan was 5.64 Â 10 6 (3.38-9.28). Median (range) times to ANC 4500/ml and PLT 420 000/ ml were 9 days (8-10) and 10 days (8-13), respectively. Median (range) duration of neutropenia with ANC o100/ ml was 4 days (3-6) ( Table 2) .
Febrile neutropenia was observed in 12 patients (100%) without documented infections. Major nonhematologic toxicities were acute and delayed vomiting in 36% of patients; grade 3 mucositis requiring total parenteral nutrition occurred in 58% of patients and lasted for a median of 5 days (range 3-9). High-dose idarubicin and alkylators in metastatic breast cancer C Bengala et al
Cardiac safety
Median (range) L-VEF was 54% (51-56) at study entry, 55% (51-56) after six courses of GET, 53% (49-55) after HD-Id, 51% (47-55) after high-dose alkylators and 55% (52-60) 6 months after treatment. One patient receiving idarubicin 60 mg/m 2 showed a reduction of L-VEF to less than 50% without signs or symptoms of heart failure. At the end of the treatment, L-VEF was less than 50% in 14.3% of the patients, but returned to 55% (range 51-55) within 3 months from the second transplant and was stable after 6 months. The baseline E/A wave ratio pattern was normal in 12 patients and balanced in two patient. After idarubicin, a balanced E/A ratio was observed in nine patients and an inverted E/A ratio in two without correlation with the dose level. The 72 h continuous ECG registration during idarubicin infusion did not show any significant modification of cardiac rhythm; one patient treated at 70 mg/m 2 reported an asymptomatic atrial flutter.
Pharmacokinetic results
At the end of infusion the plasma levels of idarubicin and idarubicinol were 7.772.0 and 26.379.7 ng/ml at 40 mg/ m 2 , and increased to 14.873.0 and 47.4712.6 ng/ml at 70 mg/m 2 (Tables 3 and 4 (Tables 3  and 4) .
Antitumor activity and survival
After induction chemotherapy, five patients had stable disease and nine patients were in partial remission. Following HD-Id, three patients in SD were converted to PR and one patient in PR was converted to CR with a conversion rate of 28.6%. According to the protocol the patient in CR after HD-Id did not receive the second course of HDC. After HD-TM, four patients in PR (two after induction and two after HD-Id) were converted to CR and one patient in SD achieved a PR with a conversion rate of 38.5%. At the end of the program, five patients were in CR (35.7%), eight in PR (57%) and one had stable disease (7%). After a median follow-up of 26 months, 13 patients have developed progressive disease and six have died; median (range) progression-free survival from first transplant is 15 months (4-25) while median overall survival has not yet been reached (Figure 1) . Table 2 Hematological toxicity and hemopoietic recovery
Days: median (range)
Idarubicin Thiotepa+melphalan
Recovery to ANC >500/ml 10 (6-13) 9 (8-10) Recovery to ANC >1000/ml 11 (7-13) 10 (8-11) Time with ANC o100/ml 9 (5-13) 4 (3-6) Time with ANC o500/ml 10 (6-14) 5 (4-6) Recovery to platelets >20 000/ml 9 (4-12) 10 (8-13) Time with platelets o20 000/ml 4 (1-11) 2 (1-7) Neutropenic fever 66% 100% Duration (days): median (range) 6 (0-11) 6 (1-9) RBC units transfused: median (range) High-dose idarubicin and alkylators in metastatic breast cancer C Bengala et al
Discussion
HDC administered as consolidation/intensification treatment in chemoresponsive breast cancer has failed to produce any significant survival advantage. [1] [2] [3] [4] This procedure therefore must still be considered investigational. More active induction regimens and the administration of multiple courses of different drugs at high-dose are among the possibilities that deserve further investigation.
The treatment program we have designed includes an induction regimen without alkylators followed by HD-Id and high-dose alkylators. Idarubicin is a lipophilic drug widely distributed in body fluids that reaches high intracellular concentrations. 15 In vitro studies have shown that idarubicin is more effective than daunorubicin in tumor cell lines displaying the MDR phenotype; 16, 17 these data suggest that idarubicin can be noncross-resistant with epirubicin. Moreover, cellular pharmacology of idarubicin and its metabolite idarubicinol suggests that idarubicin has antitopoisomerase II activity. 18, 19 Cell killing by antitopoisomerase II agents predominantly occurs during S-phase; therefore, although idarubicin is not a phase-specific drug, a prolonged infusion time increases the number of cells exposed to the drug during the most chemosensitive phase of the cell cycle. 20 For this reason, in our study, HD-Id was administered as a 48 h continuous infusion to exploit the long half-life of the parent drug and its active metabolite idarubicinol.
The plasma disposition of idarubicin we have observed seems linear, in the range from 40 to 70 mg/m 2 , most likely dependent on rapid metabolism of the drug in vivo. The elimination of idarubicinol was slightly slower than that of the parent compound, with median half-lives for different dose levels of about 40 h for idarubicin and 48 h for idarubicinol, while the overall tissue exposure, as evidenced by the AUC, was, on average, six times higher for idarubicinol as compared to idarubicin across the dose levels examined. The administration of idarubicin by continuous infusion resulted in a substantial increase in the ratio between the AUC of the parent drug and idarubicinol with respect to the conventional administration of idarubicin, in which the AUC of the metabolite is approximately three times higher than that of idarubicin: 315.44 vs 1028.49 hmg/l. 21 Finally, pharmacokinetic data provide evidence that the penetration of idarubicin and idarubicinol into the CSF is poor and is not influenced by increasing the drug dose, although CNS tissue levels cannot be predicted from these data. On the contrary, high concentrations of idarubicin into malignant brain tumor tissue after a single dose of drug have been reported by Boogerd et al.
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In the present report, we have shown that the treatment is feasible with acceptable toxicity and that the MTD of idarubicin administered over 48 h plus PBPC is 60 mg/m 2 .
To our knowledge this is the first report of HD-Id in patients with metastatic breast cancer already exposed to anthracyclines. The cardiac safety of HD-Id is excellent: no episodes of cardiac toxicity occurred and only two patients (14%) experienced a transient nonsignificant decline in L-VEF. Rose and coworkers reported an unexpected, significant decrease in L-VEF after a double course of HDC. 23 However, our data show that diastolic abnormalities expressed as balance or inversion of E/A wave ratio pattern are present without systolic dysfunction and this may be an initial expression of cardiotoxicity and a sign of myocardial disorder. Moreover, our data suggest that idarubicin was not crossresistant with epirubicin: 3/5 patients with stable disease and 1/9 in partial response after six courses of GET experienced a further cell killing and were converted to a better response category (conversion rate 28.6%). This level of activity is not negligible in patients with tumors only partially responsive (64.3%) or unresponsive (35.7%) to six courses of combination chemotherapy with adequate doses of epirubicin.
The patients not in CR after HD-Id received a second high-dose regimen with alkylators. The hemopoietic recovery and nonhemopoietic toxicities we observed were comparable with those reported after a single course of HD-TM; 7 in particular, we did not observe any symptomatic cardiotoxicity. Interestingly, high-dose alkylators produced a further conversion rate of 38.6%.
In conclusion, this study demonstrates that idarubicin 60 mg/m 2 with PBPC support can be safely given to patients pretreated with chemotherapy; in particular, no episodes of grade 3 cardiotoxicity were observed. HD-Id is active in patients with breast tumors resistant (five patients with stable disease) or only partially sensitive (nine patients in PR) to epirubicin. Finally, a second high-dose course with alkylators can induce further cell killing, with a final CR rate of 36%. Currently, 13/14 patients have already progressed with a median time to progression of 14.5 months. It is therefore clear that, in spite of its activity, HDC cannot eradicate chemoresistant cells. Novel therapies able to prevent regrowth of residual tumor cells may translate the additional killing efficacy of high-dose therapy into clinical benefit.
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